68
Views
2
CrossRef citations to date
0
Altmetric
Hepatology

Portal Vein Thrombosis in Patients with Liver Cirrhosis: What Went Wrong?

ORCID Icon, , , ORCID Icon, , , , ORCID Icon, , ORCID Icon & show all
Pages 3889-3906 | Received 26 Apr 2023, Accepted 10 Aug 2023, Published online: 27 Feb 2024

References

  • Acuna-Villaorduna A, Tran V, Gonzalez –lugo JD, Azimi-Nekoo E, Billett HH. Natural history and clinical outcomes in patients with portal vein thrombosis by etiology: a retrospective cohort study. Thromb Res. 2019;174:137–140. doi:10.1016/j.thromres.2018.12.019
  • Ogren M, Bergovits D, Byorck M, et al. Portal vein thrombosis, patients characteristics and life time risk: a population study based on 23796 consecutive autopsies. World J Gastroenterol. 2006;1(2):2115–2119. doi:10.3748/wjg.v12.i13.2115
  • Wolberg AS, Alerman M, Leiderman K, Machlus KL. Procoagulant activity in hemostasis and thrombosis: virchow’s triad revisited. Anesth Analg. 2012;114(2):275–285. doi:10.1213/ANE.0b013e31823a088c
  • Valla DC, Condat B. Portal vein thrombosis in adults: pathophysiology, pathogenesis and management. J Hepatol. 2000;32:865–871. doi:10.1016/S0168-8278(00)80259-7
  • Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet. 1999;353(9159):1167–1173. doi:10.1016/S0140-6736(98)10266-0
  • Amitrano L, Guardascione MA, Brancaccio V, et al. Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. J Hepatol. 2004;40(5):736–741. doi:10.1016/j.jhep.2004.01.001
  • Plessier A, Darwish Murad S, Hernandez Guerra M, et al. European network for vascular disorders of the liver (En-Vie). Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study. Hepatology. 2010;51:1210–1218. doi:10.1002/hep.23259
  • Chawla YK, Bodh V. Portal vein thrombosis. J Clin Exp Hepatol. 2015;5:22–40. doi:10.1016/j.jceh.2014.12.008
  • Cirera I, Bauer TM, Navasa M, et al. Bacterial translocation of enteric organisms in patients with cirrhosis. J Hepatol. 2001;34(1):32–37. doi:10.1016/S0168-8278(00)00013-1
  • Georgescu D, Iurciuc MS, Ionita I, et al. Portal vein thrombosis and gut dysbiosis: understanding the burden. Rev Chim. 2019;70(6):2181–2185. doi:10.37358/RC.19.6.7301
  • Lee EYP, Khong PL. The value of 18 FDG PET scan in detection of tumor thrombus Clin. Nucl Med. 2013;38:e60–5.
  • Lee HK, Park SJ, Yi BH, et al. Portal vein thrombosis: CT features. Abdom Imaging. 2008;33(1):72–79. doi:10.1007/s00261-007-9200-x
  • Webster GJ, Burroughs AK, Riordan SM. Portal vein thrombosis: new insight into etiology and management. Aliment Pharmacol Ther. 2005;21:1–9. doi:10.1111/j.1365-2036.2004.02301.x
  • Garcia-Pagan JC, Valla DC. Portal vein thrombosis: a predictable milestone in cirrhosis? J Hepatol. 2009;51(4):632–634.
  • European Association For The Study Of The Liver. EASL Clinical practice Guidelines: vascular diseases of the liver. J Hepatol. 2015;63(1):179–202.
  • Senzolo M, Tibbals J, Cholongitas E, et al. Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with and without cavernous transformation. Aliment Pharmacol Ther. 2006;23(6):767–775. doi:10.1111/j.1365-2036.2006.02820.x
  • Ma J, Yan Z, Luo J, Liu Q, Wang J, Qiu S. Rational classification of portal vein thrombosis and its clinical significance. PLoS One. 2014;9(11):e112501. doi:10.1371/journal.pone.0112501
  • Ponziani FR, Zocco MA, Campanele C, et al. Portal vein thrombosis: insight into physiopathology and treatment. World J Gastroenterol. 2010;16(2):143–155.
  • De Franchis R. Expanding consensus in portal hypertension report of the baveno VI consensus workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63(3):743–752. doi:10.1016/j.jhep.2015.05.022
  • Bhangui P, Lim C, Levesque E, et al. Novel classification of no-malignant portal vein thrombosis: a guide to surgical decision-making during liver transplantation. J Hepatol. 2019;71(5):1038–1050. doi:10.1016/j.jhep.2019.08.012
  • Wu M, Schuster M, Tadros M. Update on management of portal vein thrombosis and the role of novel anticoagulants. J Clin Transl Hepatol. 2019;7(2):154–164. doi:10.14218/JCTH.2018.00057
  • Kreutziger LB, Ageno W, Lee A. Management of incidental splanchnic vein thrombosis in cancer patients. Hematololgy. 2014;2014:318–320. doi:10.1182/asheducation-2014.1.318
  • Violi F, Lip GY, Cangemi R. Endotoxemia as a trigger of thrombosis in cirrhosis. Haematologica. 2016;101(4):e162–3. PMID: 27033239; PMCID: PMC5004387. doi:10.3324/haematol.2015.139972
  • Wang P, Tan F, Mu J, et al. Inhibitory effect of lactobacillus delbrueckii subsp. bulgaricus KSFY07 on Kappa-Carrageenan-induced thrombosis in mice and the regulation of oxidative damage. Cardiovasc Ther. 2022;15:4415876. doi:10.1155/2022/4415876
  • Sandrin TR, Goldstein JE, Shoemaker S. MALDI TOF MS profiling of bacteria at the strain level: a review. Mass Spectrom Rev. 2013;32(3):188. doi:10.1002/mas.21359
  • Ji B, Nielsen J. From next-generation sequencing to systematic modeling of the gut microbiome. Front Genet. 2015;6:219. doi:10.3389/fgene.2015.00219
  • Friedrich-Rust M, Nierhoff J, Lupsor M, et al. Performance of ARFI imaging for the staging of liver fibrosis: a pooled meta-analysis. J Viral Hepatol. 2012;19(2):e212–e219. doi:10.1111/j.1365-2893.2011.01537.x
  • Sirli R, Sporea I, Popescu A, Danila M. Ultrasound-based elastography for the diagnosis of portal hypertension in cirrhotics. World J Gastroenterol. 2015;21(41):11542. doi:10.3748/wjg.v21.i41.11542
  • Child CG, Turcotte JG. Surgery and portal hypertension. In: Child CG. The Liver and Portal Hypertension. Philadelphia: Saunders; 1964:50–64.
  • Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60(8):646–649. doi:10.1002/bjs.1800600817
  • Ennis J, Schultz G, Perera P, et al. Ultrasound for detection of ascites and for guidance of the paracentesis procedure: technique and review of the literature. Internat J Cl Med. 2014;5(20):1277–1293. doi:10.4236/ijcm.2014.520163
  • Paquet KJ. Prophylactic endoscopic sclerosing treatment of the esophageal wall in varices – a Prospective Controlled Randomized Trial. Endoscopy. 1982;14:4–5. doi:10.1055/s-2007-1021560
  • Forrest JA, Finlayson ND, Shearman DJ. Endoscopy in gastrointestinal bleeding. Lancet. 1974;2(7877):394–397. doi:10.1016/S0140-6736(74)91770-X
  • Ferenci P. Hepatic encephalopathy. Gastroenterol Rep. 2017;5(2):138–147. doi:10.1093/gastro/gox013
  • Larson K, Ho HH, Anumolu PL, Chen TM. Hematoxylin and eosin tissue stain in Mohs micrographic surgery; a review. Dermatol Surg. 2011;37(8):1089–1099. doi:10.1111/j.1524-4725.2011.02051.x
  • Basit SA, Stone CD, Gish R. Portal vein thrombosis. Clin Liver Dis. 2015;18:199–221. doi:10.1016/j.cld.2014.09.012
  • Georgescu D, Georgescu LA, Muntean M, Lighezan D. Duplex abdominal examination in portal vein obstruction: how much can we rely on? Ultraschall der Medizin. 2016;37:S01. doi:10.1055/s-0036-1587774
  • Margini C, Berzigotti A. Portal vein thrombosis: the role of imaging in the clinical setting. Dig Liv Dis. 2017;49(2):113–120. doi:10.1016/j.dld.2016.11.013
  • Mantaka A, Augoustaki A, Kouroumalis EA, Samonakis DN. Portal vein thrombosis in cirrhosis: diagnosis, natural history and therapeutical challenges. Ann Gastroenterol. 2018;31(3):315–329. doi:10.20524/aog.2018.0245
  • Huang X, Fan X, Zhang R, et al. Systemic inflammation and portal vein thrombosis in cirrhotic patient with gastroesophageal varices. Eur J Gastroenterol Hepatol. 2020;32(3):401–405. doi:10.1097/MEG.0000000000001526
  • Tsochartzis EA, Senzolo M, Germani G, Gatt A, Burroughs AK. Systematic review: portal vein thrombosis in cirrhosis. Aliment Pharmacol Ther. 2010;31(3):366–374. doi:10.1111/j.1365-2036.2009.04182.x
  • Zocco MA, Stasio E, De Cristofaro R, et al. Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring and portal vein thrombosis development. J Hepatol. 2009;51:682–689. doi:10.1016/j.jhep.2009.03.013
  • Papatheodoridis GV, Chrysanthos N, Cholongitas E, et al. Thrombotic risk factors and liver histologic lesions in nonalcoholic fatty liver disease. J Hepatol. 2009;51(5):931–938. doi:10.1016/j.jhep.2009.06.023
  • Costache RS, Dragomirică AS, Dumitraș EA, et al. Portal vein thrombosis: a concise review. Exp Ther Med. 2021;22:759. doi:10.3892/etm.2021.10191
  • Kelly J, Rudd A, Lewis RR, et al. Plasma D-Dimers in the diagnosis of venous thromboembolism. Arch Intern Med. 2002;162(7):747–756. doi:10.1001/archinte.162.7.747
  • Zhang DL, Hao JY, Ning Y. Value of D-dimers and protein S for diagnosis of portal vein thrombosis in patients with liver cirrhosis. J Int Med Res. 2013;41(3):664–672. doi:10.1177/0300060513483413
  • Dai J, Qi X, Li H, Guo X. Role of D-dimer in the development of portal vein thrombosis in liver cirrhosis: a metaanalysis. Saudi J Gastroenterol. 2015;21(3):165–174. doi:10.4103/1319-3767.157567
  • Zhu W, Wang Z, Tang WHW, Hazen SL. Gut microbe-generated Trimethylamine N-oxide from dietary choline is prothrombotic in subjects. Circulation. 2017;135(17):1671. doi:10.1161/CIRCULATIONAHA.116.025338
  • Nicoletti A, Ponziani FR, Biolato M, et al. Intestinal permeability in the pathogenesis of liver damage: from non-alcoholic fatty liver disease to liver transplantation. World J Gastroenterol. 2019;25(33):4814–4834. doi:10.3748/wjg.v25.i33.4814
  • Trebicka J, Bork P, Krag A, et al. Utilizing the gut microbiome in decompensated cirrhosis and acute-on-chronic liver failure. Nat Rev Gastroenterol Hepatol. 2021;18(3):167–180. doi:10.1038/s41575-020-00376-3
  • Feng G, Yang X, Li Y, Wang X, Tan S, Chen F. LPS enhances platelets aggregation via TLR4, which is related to mitochondria damage caused by intracellular ROS, but not extracellular ROS. Cell Immunol. 2018;328:86–92. doi:10.1016/j.cellimm.2018.04.002
  • VGalgano L, Guidetti GF, Torti M, Canobbio I. The controversial role of LPS in platelet activation in vitro. Int J Mol Sci. 2022;23(18):10900. PMID: 36142813; PMCID: PMC9505944. doi:10.3390/ijms231810900
  • Martyanov AA, Maiorov AS, Filkova AA, et al. Effects of bacterial lipopolysaccharides on platelet function: inhibition of weak platelet activation. Sci Rep. 2020;2020(10):12296. doi:10.1038/s41598-020-69173-x
  • Ana C, Antunes N, Pedro HL, et al. Tumor necrosis factor alpha has a crucial role in increased reactive oxygen species production in platelets of mice injected with lipopolysaccharide. Platelets. 2019;30:8, 1047–1052. doi:10.1080/09537104.2019.1588241
  • Trebicka J, Strassburg CP. Etiology and complications of portal vein thrombosis. Viszeralmedizin. 2014;30:375–380. doi:10.1159/000369987
  • Faccia M, Santopaolo F, Gasbarrini A, Pompili M, Zocco MA, Ponziani FR. Risk factors for portal vein thrombosis or venous thromboembolism in a large cohort of hospitalized cirrhotic patients. Intern Emerg Med. 2022;17(5):1327–1334. PMCID: PMC9352602. doi:10.1007/s11739-022-02928-8
  • Janssen HL, Wijhoud A, Haasma EB, et al. Extrahepatic portal vein thrombosis: etiology and determinants of survival. Gut. 2001;48:720–724. doi:10.1136/gut.49.5.720
  • Muneer M, Abdelrahman H, El-Menyar A, Zarour A, Awad A, Al-Thani H. Acute cholecystitis complicated with portal vein thrombosis: a case report and literature review. Am J Case Rep. 2015;16:627–630. doi:10.12659/AJCR.894846
  • Ozawa K, Shikino K. Pylephlebitis due to acute cholecystitis and cholangitis. BMJ. 2021;14:e244912. doi:10.1136/bcr-2021-244912
  • Georgescu D, Ionita I, Lascu A, et al. Gallstone disease and bacterial metabolic performance of gut microbiota in middle-aged and older patients. Int J Gen Med. 2022;15:5513–5531. doi:10.2147/IJGM.S350104
  • Georgescu D, Caraba A, Ionita I, et al. Dyspepsia and gut microbiota in female patients with postcholecystectomy syndrome. Int J Women’s Health. 2022;14:41–56. doi:10.2147/IJWH.S342882
  • Chawla YK, Duseja A, Dhiman RK. Review article: the modern management of portal vein thrombosis. Aliment Pharmacol Ther. 2009;30(9):881–894. doi:10.1111/j.1365-2036.2009.04116.x
  • Harding DJ, Perera MTPR, Chen F, Olliff S, Tripathi D. Portal vein thrombosis in cirrhosis: controversies and latest developments. World J Gastroenterol. 2015;21(22):6769–6784. doi:10.3748/wjg.v21.i22.6769
  • Condat B, Pessione F, Hillaire S, et al. Current outcome of portal vein thrombosis in adults: risk and benefit of anticoagulant therapy. Gastroenterology. 2001;120:490–497. doi:10.1053/gast.2001.21209
  • Amitrano L, Guardascione MA, Menchise A, et al. Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis. J Clin Gastroenterol. 2010;44:448–451. doi:10.1097/MCG.0b013e3181b3ab44
  • John BV, Konjeti R, Aggarwal A, et al. Impact of untreated portal vein thrombosis on pre and post liver transplant outcomes in cirrhosis. Ann Hepatol. 2013;12(6):952–958. doi:10.1016/S1665-2681(19)31301-8
  • Sharma AM, Zhu D, Henry Z. Portal vein thrombosis: when to treat and how? Vasc Med. 2016;21(1):61–69. doi:10.1177/1358863X15611224
  • Sogaard KK, Astrup LB, Vilstrup H, Gronbaek H. Portal vein thrombosis; risk factors, clinical presentation and treatment. BMC Gastroenterol. 2007;7:34. doi:10.1186/1471-230X-7-34
  • Luca A, Caruso S, Milazzo M, et al. Natural course of extrahepatic nonmalignant partial portal vein thrombosis in patients with cirrhosis. Radiology. 2012;265:124–132. doi:10.1148/radiol.12112236
  • Qi X, Han G, Fan D. Management of portal vein thrombosis in liver cirrhosis. Nat Rev Gastrenterol Hepatol. 2014;11:435–446. doi:10.1038/nrgastro.2014.36
  • Tzakos A, Kotnagianni VG, Tsoumani M, et al. Exploration of the antiplatelet activity profile of betulinic acid on human platelets. J Agric Food Chem. 2012;60(28):6977–6983. doi:10.1021/jf3006728
  • Nicolov M, Duse AO, Georgescu D, et al. Preliminary studies on betulinic acid crystals with organic solvents. Rev Chim. 2016;67(7):1411–1414.
  • Manzano-Robleda MC, Barranco-Fragoso B, Uribe M, Mendez-Sanchez N. Portal vein thrombosis: what is new? Ann Hepatol. 2015;14(1):20–27. doi:10.1016/S1665-2681(19)30797-5
  • Harki J, Plompen EP, van Noord D, et al. Gastrointestinal ischemia in patients with acute and chronic portal vein thrombosis. J Hepatol. 2014;60:S239–S240. doi:10.1016/S0168-8278(14)60672-3
  • Marcias I. Massive upper gastrointestinal bleeding due to splenoportal axis thrombosis in a patients with a tested JAK2 mutation; A case report and review literature. Int J Surg Case Rep. 2016;2(8):93–96. doi:10.1016/j.ijscr.2016.08.013
  • Biecker E. Gastrointetinal bleeding in cirrhotic patients with portal hypertension. Int Schol Res Notices. 2013. doi:10.1155/2013/541836l
  • Wallace A, Albadawi H, Hoang P, et al. Statins as a preventative therapy for venous thromboembolism. Cardiovasc Diagn Ther. 2017;7(Suppl 3):S207–S218. doi:10.21037/cdt.2017.09.12
  • Bordbar M, de Mutsert R, Cevval M, et al. Differential effect of statin use on coagulation markers: an active comparative analysis in the NEO study. Thromb J. 2021;19(1):45. doi:10.1186/s12959-021-00299-2
  • Vieira- Silva S, Falony G, Belda E, et al. Statin therapy is associated with lower prevalence of gut microbiota dysbiosis. Nature. 2020;581(7808):310–315. doi:10.1038/s41586-020-2269-x
  • Dias AM, Cordeiro G, Estevinho MM, et al. Gut bacterial microbiome composition and statin intake - A systematic review. Pharmacol Res Perspect. 2020;8:e00601. doi:10.1002/prp2.601
  • Sha T, Zhang Y, Li C, et al. Association of metformin use with risk of venous thromboembolism in adults with type 2 diabetes: a general-population-based cohort study. Am J Epidemiol. 2022;191(5):856–866. PMID: 34999759. doi:10.1093/aje/kwab291
  • Alqahtan S, Mahzar M. Protective effect of metformin on venous thrombosis in diabetic patients: findings from a systematic review. J Endocrinol Met. 2022;12(6):161–167. doi:10.14740/jem848
  • Montandon SA, Jornayvaz FR. Effects of antidiabetic drugs on gut microbiota composition. Genes. 2017;8:250. doi:10.3390/genes810025
  • Rodriguez J, Hiel S, Delzenne NM. Metformin: old friend, new ways of action-implication of the gut microbiome? Curr Opin Clin Nutr Metab Care. 2018;21(4):294–301. PMID: 29634493. doi:10.1097/MCO.0000000000000468
  • Quarrie R, Stawicki SP. Portal vein thrombosis: what surgeons need to know. Int J Crit Illn Inj Sci. 2018;8(2):73–77. doi:10.4103/IJCIIS.IJCIIS_71_17
  • Denninger MH, Chait Y, Casadeval N, et al. Cause of portal or hepatic vein thrombosis in adults: the role of multiple concurrent factors. Hepatology. 2000;3:587–591. doi:10.1002/hep.510310307
  • Chen H, Turon F, Hernández‐Gea V, et al. Nontumoral portal vein thrombosis in patients awaiting liver transplantation. Liv Transpl. 2016;22(3):352–365. doi:10.1002/lt.24387
  • Nery F, Carneiro P, Correia S, et al. Systemic inflammation as a risk factor for portal vein thrombosis in cirrhosis: a prospective longitudinal study. Eur J Gastroenterol Hepatol. 2021;33(1S Suppl 1):e108–e113. PMID: 33208682. doi:10.1097/MEG.0000000000001982
  • Fede G, Privitera G, Tomaselli T, Spadaro L, Purrello F. Cardiovascular dysfunction in patients with liver cirrhosis. Ann Gastroenterol. 2015;28(1):31–40.